Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Similars in SciELO
Share
Gaceta Médica Boliviana
Print version ISSN 1012-2966On-line version ISSN 2227-3662
Abstract
ROJAS CABRERA, Ernesto et al. Intralesional Application of Antimonials in the Treatment of Cutaneous Leishmaniasis. Gac Med Bol [online]. 2022, vol.45, n.1, pp.6-11. ISSN 1012-2966. https://doi.org/10.47993/gmb.v45i1.370.
Objective:
to evaluate the clinical efficacy of intralesional application of 3 versus 6 injections of Glucantime® for one or two weeks in patients with cutaneous leishmaniasis.
Methods:
quasi-experimental study. 41 patients with cutaneous leishmaniasis were included from the tropical endemic area of Cochabamba, Bolivia. Participants were randomly assigned to receive intralesional treatment with Glucantime®, in three or six applications. All patients signed a written consent to voluntarily participate in the study, approved by the ethics committee of the UMSS medical school.
Results:
evaluation of the clinical effectiveness of three or six intralesional applications of Glucantime® found no statistically significant differences between the two. Likewise, no significance differences were found regarding complete healing achieved at one month post-treatment by both application schemes.
Conclusions:
ulcer healing observed in this study was achieved independent of the scheme of either three or six intralesional applications of Glucantime® and these results are comparable to systemic treatment. Three intralesional Glucantime® applications are considered to be the minimal treatment limit for cutaneous leishmaniasis with a single ulcer smaller than three by three centimeters.
Keywords : drug administration schedule; intralesional injections; cutaneous leishmaniasis.